Wockhardt spent two decades and ₹6,800 crore rebuilding around novel antibiotics. It now holds six US FDA QIDP designations—more than any pharma company globally—and its lead drug Zaynich won FDA approval in May 2026.
Founded in 1967 by Dr. Habil Khorakiwala, Wockhardt grew through generics and debt-funded global acquisitions. By the late 2000s, corporate debt neared ₹3,800 crore, forcing a long restructuring.
Between 2013 and 2017, US FDA import alerts and a warning letter cut Wockhardt off from America's generic market. Management exited standard US generics, absorbing one-time restructuring charges to stop the bleeding.
To survive, Wockhardt sold hospitals to Fortis for about ₹909 crore and nutrition brands to Danone. In June 2020, it moved 62 branded generics to Dr. Reddy's for ₹1,850 crore, preserving cash for antibiotic R&D.
The strategic pivot produced a financial inflection. FY26 revenue rose 11% to ₹3,373 crore, EBITDA jumped 51% to ₹630 crore, and profit after tax swung from a ₹57 crore loss to a ₹199 crore profit.
Lead antibiotic Zaynich outperformed meropenem in the Phase 3 ENHANCE-1 trial, with an 89% cure rate versus 68.4% in complicated urinary tract infections. Wockhardt estimates a $9 billion addressable market and plans direct commercialization.
EBITDA margin reached 18.7% in FY26, up from 13.8%. The chart shows the operating momentum: EBITDA rose from ₹91 crore in FY24 to ₹630 crore in FY26, with Q1 FY27 adding another ₹188 crore.
Promoter share pledges fell from 52.90% in March 2024 to 14.68% by June 2026, easing margin-call fears. Institutional investors hold meaningful stakes, while the public float stays near 34.4%.
The bull case rests on Zaynich reaching a projected $1.5–2 billion peak annual sales. The honest counter-case: Wockhardt must build its own global commercial engine, manage Indian pricing discounts, and generate 50% of revenue from novel drugs within five years.
Wockhardt is no longer a commodity generics story. It is an antibiotic and biosimilars bet with regulatory hurdles cleared and a reset balance sheet. Read the full deep dive for the pipeline, financials, and valuation detail.
Read the full analysis →